These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15291854)

  • 1. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma.
    Choo R; Klotz L; Deboer G; Danjoux C; Morton GC
    BJU Int; 2004 Aug; 94(3):295-8. PubMed ID: 15291854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
    Egawa S; Matsumoto K; Suyama K; Iwamura M; Kuwao S; Baba S
    Cancer; 1999 Aug; 86(3):463-9. PubMed ID: 10430254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer.
    Choo R; Do V; Sugar L; Klotz L; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
    Can J Urol; 2004 Feb; 11(1):2118-24. PubMed ID: 15003150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
    Schmid HP
    Cancer Surv; 1995; 23():157-67. PubMed ID: 7542562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer.
    Vieth R; Choo R; Deboer L; Danjoux C; Morton GC; Klotz L
    Am J Ther; 2006; 13(5):394-9. PubMed ID: 16988533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
    Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
    J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling prostate specific antigen kinetics in patients on active surveillance.
    Zhang L; Loblaw A; Klotz L
    J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
    Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
    Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
    Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
    J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
    Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
    Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
    Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA doubling time of prostate carcinoma managed with watchful observation alone.
    Choo R; DeBoer G; Klotz L; Danjoux C; Morton GC; Rakovitch E; Fleshner N; Bunting P; Kapusta L; Hruby G
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):615-20. PubMed ID: 11395227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
    Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
    Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.